PSivida (PSDV, $2.55, $0.51, 25.00%) shares jumped after the company signed an exclusive worldwide collaborative research agreement with Pfizer Inc. (PFE, $25.79, $0.12, 0.47%) for work on PSivida's controlled drug deliver technologies. The deal calls for the Perth, Australia, nanotechnology company said it will receive up to $155 million and in development and sales milestones. Pfizer also agreed to fund the joint research program and to buy $5 million worth of pSivida shares upon entering the license agreement and another $5 million in the future.
PSD Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.